GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

GC Biopharma 006280.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

136,700

-2.43%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩1.99trn

FY2016FY2025

Net income

−₩4.67bn

FY2016FY2025

Free cash flow

−₩5.82bn

FY2016FY2025

Shareholders' equity

₩1.22trn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩1.99trn₩1.68trn₩1.63trn₩1.71trn₩1.54trn₩1.50trn₩1.37trn₩1.33trn₩1.29trn₩1.20trn
Gross profit₩554.12bn₩481.93bn₩484.63bn₩581.80bn₩520.59bn₩440.63bn₩372.32bn₩345.87bn₩366.80bn₩352.08bn
Research and development₩152.94bn₩166.20bn₩173.49bn₩191.35bn₩146.03bn₩137.99bn₩126.67bn₩122.03bn₩108.64bn₩112.28bn
Operating income₩69.15bn₩32.11bn₩34.44bn₩100.65bn₩73.74bn₩50.28bn₩40.29bn₩50.24bn₩90.30bn₩78.45bn
Net income−₩4.67bn−₩26.28bn−₩26.63bn₩65.45bn₩123.21bn₩81.05bn−₩3.64bn₩34.43bn₩53.25bn₩62.97bn
Diluted earnings per share-409.51-2,302.62-2,333.425,734.8610,795.557,101.33-318.713,016.641,234.135,462.08

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩2.97trn₩2.74trn₩2.64trn₩2.53trn₩2.46trn₩2.15trn₩1.96trn₩1.72trn₩1.70trn₩1.55trn
Total liabilities₩1.58trn₩1.26trn₩1.10trn₩958.90bn₩962.39bn₩882.09bn₩775.22bn₩597.20bn₩594.87bn₩491.60bn
Debt₩253.50bn₩339.51bn₩84.89bn₩278.80bn₩280.34bn₩194.16bn₩406.38bn₩328.77bn₩312.98bn₩248.85bn
Shareholders' equity₩1.22trn₩1.25trn₩1.30trn₩1.33trn₩1.27trn₩1.12trn₩1.05trn₩1.06trn₩1.04trn₩993.07bn
Shares outstanding11m11m11m11m11m11m11m11m43m12m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations₩99.46bn−₩53.46bn−₩5.47bn₩119.15bn₩125.98bn₩35.97bn₩40.29bn₩14.41bn₩57.88bn−₩1.74bn
Capital spending−₩105.28bn−₩42.39bn−₩125.99bn−₩94.69bn−₩102.32bn−₩82.88bn−₩127.45bn−₩41.39bn−₩29.49bn−₩98.67bn
Free cash flow−₩5.82bn−₩95.85bn−₩131.46bn₩24.46bn₩23.66bn−₩46.90bn−₩87.16bn−₩26.98bn₩28.39bn−₩100.41bn
Dividends paid−₩18.83bn−₩19.53bn−₩24.82bn−₩23.99bn−₩18.51bn−₩12.72bn−₩12.38bn−₩15.33bn−₩15.33bn−₩20.50bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩421.18bn₩435.53bn₩497.75bn₩609.49bn₩500.26bn₩383.78bn₩440.85bn₩464.87bn
Gross profit₩109.55bn₩145.49bn₩140.28bn₩145.90bn₩155.20bn₩112.75bn₩121.53bn₩145.49bn
Operating income₩1.73bn₩41.29bn₩4.60bn₩29.22bn₩44.85bn₩7.96bn—₩53.28bn
Net income₩1.98bn₩20.47bn−₩88.30bn₩15.95bn₩37.99bn₩29.70bn−₩27.29bn₩33.26bn
Diluted earnings per share173.781,793.85-7,736.951,397.073,328.522,601.85-2,391.482,914.37
Cash from operations₩19.77bn−₩24.53bn₩49.39bn₩139.65bn−₩3.36bn−₩86.21bn₩41.73bn₩17.0m
Capital spending−₩18.59bn−₩37.89bn−₩29.74bn−₩41.78bn−₩19.80bn−₩13.96bn−₩7.68bn−₩8.81bn
Free cash flow₩1.19bn−₩62.42bn₩19.65bn₩97.86bn−₩23.16bn−₩100.17bn₩34.05bn−₩8.79bn
Total assets₩2.82trn₩2.78trn₩2.97trn₩3.19trn₩3.10trn₩3.01trn₩2.74trn₩2.80trn
Debt₩310.43bn₩260.65bn₩253.50bn₩232.81bn₩231.85bn₩329.63bn₩339.51bn₩339.44bn
Shareholders' equity₩1.24trn₩1.23trn₩1.22trn₩1.30trn₩1.28trn₩1.25trn₩1.25trn₩1.29trn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue5.2%5.8%6.6%
Operating income-11.8%6.6%-2.8%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin28.2%30.0%30.5%29.7%
Operating margin2.8%3.4%3.6%4.4%
Net margin-0.8%0.1%2.1%2.8%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-388.3-78.0-53.822.620.257.2-415.745.1183.128.7
Price to sales0.91.20.90.91.63.11.11.27.61.5

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 30 Mar 2026.

FY2026FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Paid in the year1,500.003,000.001,750.002,000.001,500.001,000.001,000.001,250.00
  • 21-for-20 split · 7 Jun 2013
  • 1-to-0.2 reverse split · 14 Feb 2002
  • 1-to-0.1864 reverse split · 26 Jan 1999
  • 1.03-for-1 split · 4 Jan 1993

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.